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Abstract
Background: The aim of this study was to determine the relationship between a purported luteinizing hormone/
chorionic gonadotropin (LHCGR) high function polymorphism (rs4539842/insLQ) and outcome to controlled ovarian
hyperstimulation (COH).
Methods: This was a prospective study of 172 patients undergoing COH at the Fertility and IVF Center at GWU.
DNA was isolated from blood samples and a region encompassing the insLQ polymorphism was sequenced. We
also investigated a polymorphism (rs4073366 G > C) that was 142 bp from insLQ. The association of the insLQ and
rs4073366 alleles and outcome to COH (number of mature follicles, estradiol level on day of human chorionic
gonadotropin (hCG) administration, the number of eggs retrieved and ovarian hyperstimulation syndrome (OHSS))
was determined.
Results: Increasing age and higher day 3 (basal) FSH levels were significantly associated with poorer response to
COH. We found that both insLQ and rs4073366 were in linkage disequilibrium (LD) and no patients were
homozygous for both recessive alleles (insLQ/insLQ; C/C). The insLQ variant was not significantly associated with any
of the main outcomes to COH. Carrier status for the rs4073366 C variant was associated (P = 0.033) with an
increased risk (OR 2.95, 95% CI = 1.09-7.96) of developing OHSS.
Conclusions: While age and day 3 FSH levels were predictive of outcome, we found no association between insLQ and
patient response to COH. Interestingly, rs4073366 C variant carrier status was associated with OHSS risk. To the best of our
knowledge, this is the first report suggesting that LHCGR genetic variation might function in patient risk for OHSS.
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Background
Controlled ovulation hyperstimulation (COH) is the
cornerstone of assisted reproduction. The use of exogen-
ous gonadotropins subverts the natural process of single
follicular dominance and allows for the recruitment and
maturation of multiple ova during the ovarian cycle. Al-
though this technique has vastly enhanced the potential
for in vitro fertilization (IVF) success, individual patients
still have disparate responses. Various phenotypic predic-
tors of ovarian responsiveness (i.e. ovarian reserve testing
(ORT)) [1-4] have been used to titrate doses of fertility
medications. Despite such predictors, gonadotropin dosing
remains somewhat empiric and thus, patients risk under
or over responding (ovarian hyperstimulation syndrome
(OHSS)) to these drugs. Pharmacogenetic biomarkers
offer promise for aiding in the a priori determination of
patient response to COH [5] and minimizing complica-
tions. To date, most work has focused on common variant
alleles of follicle stimulating hormone receptor (FSHR)
[6-17], estrogen receptor (ESR) [6-8,18-20] and aromatase
(CYP19A1) [6,21] genes as well as several other genetic
loci [8,10,22,23] which have offered some promising pre-
dictive biomarkers for COH outcome.
The luteinizing hormone receptor (LHR) protein is a G
protein-coupled hormone receptor (GPCR) [24] and is
expressed in numerous tissues including the gonads
[25,26], uterus [26-28], fallopian tubes [29], placenta and
fetus [30]. Both LH and human chorionic gonadotropin
(hCG) are endogenous ligands for LHR [31] with the latter
also employed during COH. Prior to ovulation, FSH and
estradiol both increase pituitary production of LH and in-
duce LHR expression in the ovaries where LHR functions
in promoting follicular maturation, lutenization and ovula-
tion [32]. During assisted reproduction, it is believed that
hCG administration (i.e. hCG trigger) activates LHR-
mediated signaling. The pharmacological use of hCG for
COH has been implicated in the increased ovarian vascu-
lar permeability associated with OHSS, an iatrogenic com-
plication of COH [33-36].
LHR is encoded by the luteinizing hormone/chorionic
gonadotropin receptor (LHCGR) gene (~69 kb) located on
chromosome 2p21 [37-39]. LHCGR harbors at least 300
known polymorphisms [40-42] some of which having a
significant impact on sexual development and fertility
[43-51]. Recently, a 6 base-pair (CTCCAG) insertion in
exon 1 (rs4539842; insLQ) has been reported that results
in the addition of two amino acids (Leu-Gln) in the signal
peptide region of the receptor [42,52-54]. The allelic fre-
quency of the insLQ polymorphism is approximately 0.3
in individuals of Caucasian and African descent [54,55].
Structurally, insLQ impacts LHR by potentially altering
protein folding, trafficking and membrane insertion. Func-
tionally, the insLQ variant LHR protein displays higher ac-
tivity in cell culture potentially due to improved trafficking
and increased cell surface expression, but unrelated to al-
terations in hCG binding [52]. Breast cancer patients car-
rying the insLQ allele exhibit shorter disease-free survival
than non-carriers [52,53]. In addition, LHCGR resides near
a potential susceptibility locus for polycystic ovary syn-
drome (PCOS), which is characterized by anovulation/
oligo-ovulation and elevated androgen levels [56]. In a
small case/control study (n = 72), insLQ was detected at a
higher level (40.5%) in patients who experienced ovarian
hyperstimulation syndrome (OHSS) compared to controls
(27.5%), but this did not achieve statistical significance po-
tentially due to a small sample size [57].
Patient response to COH is multi-factorial in nature. To
date, there is no reliable test or algorithm that combines
both genetic and clinical factors for predicting patient re-
sponse to fertility therapy. As a result, the focus of this on-
going work is to identify genetic factors that are predictive
of clinical response to COH. The insLQ allele appears to
result in an LHR protein with increased in vitro activity; it
is therefore possible that this polymorphism could signifi-
cantly impact patient response to COH. The objective of
this study was to investigate the relationship between the
LHCGR insLQ and clinical response to COH. Interest-
ingly, the results suggest that insLQ has little impact on
COH outcome. However, carriers of a single nucleotide
polymorphism (rs4073366 G >C) nearby insLQ exhibited
an increased risk of developing OHSS.
Methods
This study was approved by George Washington University
Institutional Review Board. Written informed consent
was obtained from the participants of this study. The
study was open to all adult (>18 years of age), female
patients seeking treatment at the GW Fertility and IVF
Center at GWU Medical Center. One hundred seventy-
two patients were recruited into the study from 2010–2011.
All IVF patients being monitored while taking injectable
gonadotropins were invited to participate. Prior to begin-
ning treatment, all patients had undergone an evalu-
ation that included ovarian reserve testing, semen
analysis (male partner), uterine cavity study and thyroid
screening. Controlled ovarian stimulation was accom-
plished with either luteal down regulation using a GnRH
agonist (leuprolide acetate; TAP Pharmaceuticals)
followed by recombinant FSH (Follistim; Merck & Co; or
Gonal-F, Serono) administration or with recombinant FSH
(Follistim; Merck & Co; or Gonal-F, Serono) administra-
tion in combination with a GnRH antagonist (Antagon;
Merck & Co). The initial FSH dose was dependent upon
patient age and basal ovarian reserve testing. After initial
follicular monitoring (serum estradiol and transvaginal
ultrasound assessments), FSH dosing was titrated based
upon the ovarian response. hCG trigger was withheld for
levels E2 over 4000 pg/ml thus minimizing risk for OHSS.
O’Brien et al. Reproductive Biology and Endocrinology 2013, 11:71 Page 2 of 8
http://www.rbej.com/content/11/1/71
Both control and OHSS groups had similar risk factors in-
cluding those identified at time of hCG trigger. Ovarian
response to gonadotropin was observed. The primary end-
point of the study was the estradiol level on day of hCG
injection. Secondary clinical endpoints included number
of ovarian follicles counted on day of hCG number of
eggs retrieved and the incidence of OHSS. Ovarian
hyperstimulation syndrome was defined clinically based on
the criteria established by Navot [58,59].
Approximately 5 mL of blood was collected for genetic
analysis at the GW IVF Center. Total genomic DNA was
extracted from 200 μl EDTA anti-coagulated venous blood
using a QiaCube automated instrument with the QIAamp
DNA Blood Mini Kit (Qiagen, Valencia, CA). The samples
were frozen at −80°C until the time of genotyping. A 291
base-pair target region encompassing (rs4539842/insLQ
and rs4073366 was amplified using 10 pmol/μl forward
(5’-CACTCAGAGGCCGTCCAAG-3’) and reverse (5’-
GGAGGGAAGGTGGCATAGAG-3’) primers [42]. PCR
was performed in a reaction volume of 50 μl, including
10.0 μl of 5X Reaction Buffer, 0.5 μl GoTaq L nucleotide
mix, 6 μl MgCl2 DNA Polymerase (Promega Corp,
Madison, WI), 3.75 μl of H2O, and 10.0 μl of genomic
DNA. The PCR cycling conditions were as follows:
1 cycle of 95°C for 2 minutes, followed by 32 cycles of
95°C for 30 seconds, 56°C for 30 seconds and 72°C for
30 seconds and a 7 min final extension at 72°C. PCR
products were purified (GeneClean Turbo, MP Biome-
dicals, Solon, OH) and 20–40 ng/μl of samples were
sequenced using BigDye Terminator technology (Life Tech-
nologies, Grand Island, NY) by Eurofins MWG Operon
(Huntsville, AL). Multiple sequence alignments were carried
out using ChromasPro software (Technelysium Pty Ltd).
Patient differences in mean outcomes (estradiol level,
number of follicles, number of eggs retrieved) related to
genotype were tested using a step-down bootstrap
resampling method (the STEPBOOT option in PROC
MULTTEST in SAS) [60]. This method adjusts for mul-
tiple comparisons while maintaining relatively good statis-
tical power compared to other methods and is applicable
to both normal and non-normally distributed data [60].
Outcome differences were first tested separately for each
polymorphism, followed by comparing combinations of al-
leles for the two polymorphisms. The association between
the distributions of patients across alleles for the two poly-
morphisms was tested by Fisher’s Exact Test. Multivari-
able model predicting each outcome was calculated using
linear regression for estradiol level and negative-binomial
regression for number of follicles and eggs retrieved. The
latter method is an extension of Poisson regression. SAS
v.9.2 (SAS Institute, Cary, NC) was used for all statistical
analyses. Polymorphisms and were analyzed for Hardy-
Weinberg equilibrium and linkage disequilibrium (LD)
using PyPop: Python of Population Genomics software
[61], CubeX [62] and SPSS (IBM, Armonk, NY). Un-
adjusted odds ratios for OHSS risk were determined using
SAS v.9.2 and SPSS.
Results
A total of 172 patients underwent IVF and were geno-
typed. The mean age of the patient population was
36.8 years old (Table 1). The majority of the population
was Caucasian (57.0%) followed by Asian/Pacific Islander
(15.7%), non-Hispanic, African American (11.1%) and
Hispanic (2%). Because there were few Hispanic patients,
for analysis we grouped these individuals with those for
which no self-identified ethnic/ancestral information was
available (16.3% of sample). Median levels of ovarian re-
serve markers TSH, day 3 follicle-stimulating hormone
(FSH) and day 3 estradiol (E2) levels, were 1.8 IU/ml,
7.0 IU/L, and 40.8 pg/ml, respectively. On average, patient
gonadotropin stimulation lasted 12 days. Mean E2 levels
on the day of hCG administration was 1780 pg/ml and the
median number of follicles and eggs retrieved was 10 and
9, respectively. Eighteen patients (10.5%) experienced
moderate to severe OHSS (Table 1). The OHSS cases in
our sample were similar to the 154 non-OHSS patients on
age and most relevant clinical variables, with the exception
of being more likely to be Black, less likely to be Asian.
OHSS cases also had higher numbers of follicles, a higher
mean estradiol level on day of hCG and more eggs re-
trieved (Table 1). These three clinical differences were
expected based on the nature of OHSS.
Recently, a novel, potentially inactivating, mutation
was detected that resided within the insLQ insertion
(CTGCA >CG) in a patient with poor oocyte recovery fol-
lowing IVF [44]. This mutation would not have been
identified using fragment analysis (the commonly
employed method for detecting insLQ). As a result, we
analyzed insLQ through direct sequencing of a 291
base-pair region of exon/intron 1. As shown in Table 2,
relative allelic proportions for no-insLQ/no-insLQ, no-
insLQ/insLQ and insLQ/insLQ were ~0.62, 0.34 and
0.035, respectively (n = 172). Another polymorphism,
rs4073366 G > C, occurs ~142 bp downstream of insLQ
and was detected during sequencing. We attempted alter-
native methods (TaqMan® probe, alternative primer pairs)
to omit rs4073366 from our study of insLQ, but these
yielded unreliable results. Consequently, we included this
single nucleotide polymorphism (SNP) in our analysis be-
cause of its potential impact on any apparent associations
between insLQ and COH outcome. For rs4073366, G/G,
G/C and C/C variants occurred at relative proportions of
~0.72, 0.25 and 0.03, respectively in our patient popula-
tion. Both variants were in Hardy-Weinberg equilibrium
(HWE) and insLQ and rs4073366 were in significant LD
(D’ = 1.0, P < 0.0001) as determined by pair-wise LD esti-
mation (Table 2) (49). Homozygosity or heterozygosity for
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insLQ was associated with not being CG or CC for
rs4073366 (Table 3, P = 0.012). In addition, we did not find
any individuals who were homozygous for both insLQ and
rs4073366, nor did we identify any patients who had the
insLQ, rs4073366 “C” haplotype (data not shown).
Of the 172 patients, up to 17 patients were excluded
(depending on the clinical endpoint) from multivariable
analysis because of missing data values related to being
screened at outside centers that did not have complete
ovarian reserve testing or they did not undergo follicular
monitoring on day of hCG administration. Both age and
ORT (day 3 FSH, TSH and E2 levels) have been prognostic
clinical indicators of outcome to COH (52). As a result, re-
gression models predicting estradiol level on day of HCG,
number of follicles, and number of eggs retrieved included
age, day 3 FSH level, day 3 estradiol levels, and the insLQ
and rs4073366 polymorphisms as covariates. In the
multivariable models (Table 4), patient age was signifi-
cantly associated with lower E2 levels on day of hCG
(P = 0.03), fewer number of follicles (P < 0.0001) and a
lower number of eggs retrieved (P = 0.0002). Increasing
basal FSH level was associated with fewer follicles
(P = 0.009) and eggs retrieved (P = 0.0002), but not E2
levels (P = 0.46) on day of hCG. All three main out-
comes were positively correlated with each other
(Spearman r, P < 0.0001) (data not shown). Finally, self-
identified race/ethnicity was not significantly associated
with any of the three main patient outcome measures
(data not shown).
None of the pairwise differences comparing estradiol
levels, number of follicles, and number of eggs retrieved
among the 3 insLQ genotypes reached statistical signifi-
cance (not shown). Similarly, results for rs4073366 geno-
type were also not significant for these three outcomes
(not shown). We next examined the 6 non-zero combin-
ation genotypic groups and, again, found no significant
differences for any of the outcomes when each mean
was compared to the overall mean (Table 5). However,
there was a non-significant trend for those individuals
who did not carry insLQ and were heterozygous (GC)
for rs4073366 (i.e. no-insLQ/no-insLQ + CG) to have in-
creased mean estradiol level on day of hCG compared to
the mean across all other groups (P = 0.10). The insLQ
Table 1 Demographic, clinical, and genetic characteristics of the study sample (N = 172)
Total OHSS Cases Controls
Mean age (SD), Years 36.8 (4.1) 35.2 (2.9) 37 (4.2)
Race* – – –
White non-Hispanic 98 (57.0) 12 (66.7) 86 (55.8)
Black, non-Hispanic 19 (11.1) 5 (27.8) 14 (9.1)
Asian/Pacific Islander 27 (15.7) 1 (5.6) 26 (16.9)
Hispanic/Missing 28 (16.3) 0 (0.0) 28 (18.2)
TSH (IU/mL)** 1.8 (1.2-2.5) 1.8 (1.5-2.1) 1.8 (1.2-2.6)
Day 3 FSH level (IU/L)** 7.0 (5.4-8.5) 6.3 (4.5-7.3) 7.0 (5.5-8.5)
Day 3 Estradiol level (pg/mL)** 40.8 (30.0-55.7) 41.6 (33.3-57.8) 39.0 (30.0-54.7)
Total number of follicles** 10.0 (6.0-15) 18.0 (13.0-24.0) 9.0 (5.0-12.0)
Total number of days stimulated ** 12 (10–13) 12 (11–13) 12 (10–13)
Estradiol level day of hCG ** 1780 (1136–2401) 2606 (1953–3436) 1735 (988–2254)
Total number of eggs retrieved ** 9 (5–14) 18 (13–23) 8 (4–13)
* All categorical variables are presented as N (%).
** Presented as median (IQR) due to highly skewed distributions.
Table 2 Allelic frequencies and linkage disequilibrium for
the rs4539842 (insLQ) and rs4073366 polymorphisms
Variant Frequency (n = 172) D’ r2 LD P-valuea
rs4539842 (insLQ) – – – –
no-insLQ/no-insLQ 0.622 (107) – – –
no-insLQ/insLQ 0.340 (59) – – –
insLQ/insLQ 0.035 (6) – – –
– – –
rs4073366 – – – –
GG 0.721 (124) – – –
GC 0.250 (43) – – –
CC 0.029 (5) – – –
insLQ /rs4073366 – 1.00 0.0474 <0.0001
a Both variants were in Hardy-Weinberg equilibrium (HWE).
Table 3 Frequency of insLQ and rs4073366 (N = 172)*
no-insLQ/no-insLQ no-insLQ/ insLQ insLQ/insLQ
GG 68 (39.5%) 50 (29.1%) 6 (3.5%)
CG 34 (19.8%) 9 (5.2%) 0
CC 5 (2.9%) 0 0
*n (%), Fisher’s exact test for association between insLQ and rs4073366:
P = 0.012.
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polymorphism (and rs4073366) was not associated with
IVF protocol type, age, or basal FSH or E2 levels (data
not shown).
The insLQ variant is purportedly a high-function allele
and, accordingly, might place patients at a higher risk of
OHSS. As a result, we tested whether either insLQ or
rs4073366 were associated with an increased risk of
OHSS. Because of the small number of OHSS patients, lo-
gistic regression analyses were performed without adjust-
ment for covariates. Intriguingly, the insLQ variant was
not associated with OHSS by either genotype (P = 0.788)
(data not shown) or insLQ carrier status (Table 6). There
was a non-significant (P = 0.07) trend towards an associ-
ation between rs4073366 genotype and OHSS. When
rs4073366 carrier status was included in our analysis, car-
riers of the rs4073366 C allele exhibited a significantly
(P = 0.033) higher risk of OHSS (OR = 2.95, 95% CI = 1.09-
7.96). Further haplotype analysis revealed that only the no-
insLQ/C haplotype was significant (P = 0.023) for OHSS
risk (OR = 2.46, 95% CI 1.11-5.46) (data not shown).
Discussion
LHR-mediated signaling plays an important role in pa-
tient response to exogenous gonadotropins (i.e. hCG)
administered during COH and inter-individual variability
in LHR activity could significantly impact outcome. As a
result, we investigated whether LHCGR genetic variation
influences response to COH. We focused our analysis
on the insLQ polymorphism (rs4539842) and the
rs4073366 G > C SNP located downstream of insLQ in
intron 1. We found that insLQ was not associated with
patient response to COH, nor was it a predictor for
OHSS. Therefore, it is possible that the improved function
conferred to LHR by this polymorphism in vitro [52] is
not reflective of the situation in the ovaries. Moreover,
insLQ activity was previously investigated in HEK-293
cells which may not accurately replicate the behavior of
the insLQ receptor variant ovarian granulosa cells [52]. In
contrast, we found that carriers of the rs4073366 “C” allele
exhibited a ~3-fold increased risk of developing OHSS.
Very little information exists regarding polymorphisms
that are predictive of patients developing OHSS. For ex-
ample, the FSHR Thr307Ala polymorphism has been
linked with iatrogenic OHSS in an Indian population
[63], but not in European [9] or Brazilian patients [64].
The well-studied Asn680Ser FSHR polymorphism has
not been associated with OHSS, but it is potentially pre-
dictive of the severity of symptoms [9]. In addition,
BMP15 variation, such as the rs3810682 SNP (OR = 2.7,
95% CI = 1.3-5.7), has also been implicated in OHSS
[23,65]. Finally,VEGFA gene variation was recently iden-
tified as a risk allele (OR = 3.4, 95% CI = 1.01-11.7) for
OHSS [66]. Given the paucity of genetic risk factors for
OHSS, one of the most significant findings of this work
Table 4 Adjusted regression of demographic, clinical and genetic predictors of estradiol level on day of hCG, follicle
count, and egg count*
Factor Estradiol Level on Day of hCG (N = 157)a Number of Follicles (N = 155)b Number of Eggs Retrieved (N = 160)c
Estimate 95% CI P-Value Estimate 95% CI P-Value Estimate 95% CI P-Value
Age −48.2 −90.3, -6.1 0.03 0.939 0.918, 0.961 <0.0001 0.951 0.927, 0.977 0.0002
Day 3 FSH level −10.3 −38.0, 17.3 0.46 0.976 0.958, 0.994 0.0097 0.953 0.930, 0.977 0.0002
Day 3 Estradiol level −2.5 −7.7, 2.7 0.34 0.999 .997, 1.002 0.57 0.998 0.995, 1.000 0.08
insLQ/insLQ, GG 5.9 −818.3, 830.2 0.98 0.963 0.617, 1.503 0.32 0.647 0.380, 1.111 0.11
no-insLQ/insLQ, GG −197.2 −538.9, 144.4 0.26 0.909 0.755, 1.096 0.87 0.952 0.772, 1.174 0.64
no-insLQ/no-insLQ, CC −784.1 −1,682.0, 113.7 0.09 0.903 0.557, 1.63 0.68 0.665 0.372, 1.189 0.17
no-insLQ/no-insLQ, CG 163.8 −224.3, 551.9 0.41 1.210 0.985, 1.488 0.07 1.211 0.963, 1.523 0.10
* Estimates adjusted for all other variables presented.
a Linear regression with estimates of change in mean estradiol levels (pg/ml).
b Negative binomial regression with estimates of relative odds of number of follicles.
c Negative binomial regression with estimates of relative odds of number of eggs retrieved.
Table 5 Mean (SD) of estradiol level, number of follicles and number of eggs retrieved by insLQ and rs4073366±
Number of patients Estradiol level Number of follicles Number of eggs retrieved
no-insLQ/no-insLQ + GG 64-66 1819.5 (986.3) 9.8 (5.7) 9.3 (6.7)
no-insLQ/ insLQ + GG 48-49 1922.4 (1033.5) 10.9 (6.7) 11.4 (8.8)
insLQ/insLQ + GG 6 1946.0 (860.6) 10.3 (8.9) 6.7 (6.3)
no-insLQ/no-insLQ + CG 32-34 2156.1 (1009.4.0)* 13.5 (7.4) 13.3 (7.9)
no-insLQ/ insLQ + CG 8-9 1232.3 (700.3) 7.8 (3.7) 9.4 (3.7)
no-insLQ/no-insLQ + CC 5 1201.6 (464.9) 10.4 (7.4) 7.2 (0.83)
* P = 0.10.
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was the association of rs4073366 C allele carrier status
with increased risk of OHSS (OR = 2.95, 95% CI 1.09-
7.96, Table 6) during COH. Furthermore, it seems that
the effect of rs4073366 on OHSS risk was largely related
to the no-insLQ/C haplotype (OR = 2.46, 95% CI 1.11-
5.46) (data not shown). This interesting finding requires
further investigation in other COH populations and sug-
gests that the LHCGR genetic variation influences OHSS
development. A recent genome-wide association study
found that LHCGR was associated with serum steroid
hormone binding globulin (SHBGs) levels (62), which
could result in elevated serum concentrations of andro-
gens and estrogen. However, the impact of LHCGR poly-
morphisms (i.e. insLQ, rs4073366) on SHBG levels in
not currently known.
While rs4073366 is a potential predictor of OHSS risk,
the functional consequences of this polymorphism on
LHR function are yet to be elucidated. rs4073366 has a
major allele of “C” on the “+” strand (“G” on the “-“strand
in this study) and resides in a cryptic 3’ splice acceptor site
(data not shown) which could potentially impact LHCGR
mRNA processing yielding a splice variant with altered ac-
tivity [67]. In addition, the intronic region surrounding
rs4073366 is complementary to APOE mRNA and has
been associated with decreased risk of Alzheimer’s disease
(AD) in males carrying the APOE ε4 allele [67]. Given that
apolipoprotein E is important for cholesterol uptake and
steroidogenesis, and genetic variation in APOE has been
linked to reproductive efficiency [68-70], it is possible that
rs4073366 may alter response to fertility drugs via modu-
lation of APOE mRNA stability. Although beyond the
scope of this investigation; future work is focused on in-
vestigating the molecular consequences of rs4073366 on
LHCGR function.
Conclusions
Outcome to COH is multi-factorial, variable and unpre-
dictable. There have been few studies that have investi-
gated LHCGR variability and its influence on COH.
Here, we provide the first report of an association be-
tween LHCGR genetic variability and OHSS risk. The
relevance of the rs4073366 polymorphism OHSS should
be evaluated in additional patient populations. In
addition, because OHSS is multigenic in nature, future
work is warranted to investigate whether rs4073366,
and other LHCGR variants, genetically interact with
other loci to predict patient response to COH.
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